| 1 | ALDH1A1/SORD ratio | GCST90313248 | 124.88 |
| 2 | Polycystic ovarian syndrome | FING00001182 | 104.57 |
| 3 | Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093049 | 97.93 |
| 4 | Open wound of foot except toe(s) alone (PheCode 871.3) | GCST90476286 | 87.49 |
| 5 | Cryptic phenotype that captures alpha-1-antitrypsin deficiency severity | GCST90101825 | 82.01 |
| 6 | Treatment or medication use - rosuvastatin (UKB data field 20003_1141192410) | GCST90042539 | 76.16 |
| 7 | Job involves shift work | Employment | UKBB00000385 | 64.92 |
| 8 | EHMT2 levels | GCST90241442 | 62.71 |
| 9 | Triglycerides to total lipids in medium LDL percentage (UKB data field 23623) | GCST90269720 | 59.59 |
| 10 | Right hippocampal volume | GCST90267974 | 59.52 |
| 11 | MOG/PTPRN2 ratio | GCST90315475 | 59.07 |
| 12 | DNAJA2/FIS1 ratio | GCST90314501 | 58.27 |
| 13 | Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592) | GCST90269689 | 58.26 |
| 14 | CD83/TREM2 ratio | GCST90313908 | 57.06 |
| 15 | Saturated fatty acids to total fatty acids percentage | GCST90502199 | 56.48 |
| 16 | Linoleic acid levels | GCST90498306 | 56.33 |
| 17 | Smoking status - Previous | Smoking | UKBB00000781 | 55.72 |
| 18 | NADK/S100A11 ratio | GCST90315513 | 54.18 |
| 19 | Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579) | GCST90269676 | 54.17 |
| 20 | Linoleic acid to total fatty acids percentage | GCST90502321 | 53.90 |
| 21 | Triglycerides to total lipids in large LDL percentage (UKB data field 23618) | GCST90269715 | 53.38 |
| 22 | AXIN1/CLIP2 ratio | GCST90313404 | 53.35 |
| 23 | Raw carrot liking | GCST90094818 | 52.49 |
| 24 | Triglycerides in large VLDL | GCST90498280 | 52.45 |
| 25 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 80) | GCST90320643 | 52.38 |
| 26 | Phospholipids to total lipids in very small VLDL percentage (UKB data field 23604) | GCST90269701 | 52.19 |
| 27 | ITGB1/SELP ratio | GCST90315230 | 51.54 |
| 28 | COL4A1 levels | GCST90468818 | 51.39 |
| 29 | Phospholipids to total lipids ratio in very large HDL | GCST90093013 | 51.22 |
| 30 | 5,6-dihydrouridine levels | GCST90199767 | 50.98 |
| 31 | Triglyceride levels | GCST90278645 | 50.74 |
| 32 | Cholesteryl esters to total lipids in small VLDL percentage (UKB data field 23601) | GCST90269698 | 50.65 |
| 33 | Linoleic acid to total fatty acids percentage (UKB data field 23456) | GCST90269553 | 50.62 |
| 34 | Cholesterol in Large VLDL | GCST90498123 | 50.29 |
| 35 | Saturated fatty acids to total fatty acids percentage | GCST90502205 | 49.72 |
| 36 | Cholesterol to total lipids in large VLDL percentage (UKB data field 23590) | GCST90269687 | 49.20 |
| 37 | Phospholipids to total lipids in large LDL percentage (UKB data field 23614) | GCST90269711 | 47.96 |
| 38 | NCK2/PLA2G4A ratio | GCST90315524 | 47.75 |
| 39 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502160 | 47.68 |
| 40 | 3,4-dihydroxybutyrate levels | GCST90199816 | 47.51 |
| 41 | Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588) | GCST90269685 | 47.34 |
| 42 | GRP levels | GCST90241242 | 47.06 |
| 43 | PGLYRP2 levels | GCST90470220 | 46.59 |
| 44 | Ratio of linoleic acid to total fatty acids | GCST90092881 | 46.37 |
| 45 | Triglycerides to total lipids in IDL percentage (UKB data field 23613) | GCST90269710 | 46.34 |
| 46 | LGALS8/VWF ratio | GCST90315322 | 46.29 |
| 47 | Right-hemisphere salience/ventral attention network to putamen white-matter structural connectivity | GCST90302819 | 46.12 |
| 48 | Cholesterol to total lipids in IDL percentage (UKB data field 23610) | GCST90269707 | 46.06 |
| 49 | Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586) | GCST90269683 | 45.56 |
| 50 | BTD levels | GCST90468477 | 45.48 |
| 51 | C9 Carnitine levels in chronic kidney disease | GCST90257682 | 45.11 |
| 52 | Linoleic acid to total fatty acids percentage | GCST90502017 | 45.01 |
| 53 | Triglycerides to total lipids in small LDL percentage (UKB data field 23628) | GCST90269725 | 44.94 |
| 54 | Degree of unsaturation | GCST90502748 | 44.81 |
| 55 | Cholesteryl Esters in Large VLDL | GCST90498154 | 44.64 |
| 56 | Saturated fatty acids to total fatty acids percentage | GCST90502685 | 44.28 |
| 57 | PCDH17/ROBO1 ratio | GCST90315604 | 44.25 |
| 58 | Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583) | GCST90269680 | 44.07 |
| 59 | Cholesteryl esters to total lipids in IDL percentage (UKB data field 23611) | GCST90269708 | 43.56 |
| 60 | PLXDC2 levels | GCST90470264 | 43.47 |
| 61 | Ovarian dysfunction | FING00001133 | 43.35 |
| 62 | Cholesteryl Esters in Small HDL | GCST90499386 | 43.15 |
| 63 | Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093051 | 43.11 |
| 64 | DAB2/FKBP5 ratio | GCST90314363 | 43.10 |
| 65 | AXIN1/DOK2 ratio | GCST90313406 | 43.07 |
| 66 | IDP dMRI ProbtrackX FA cst r | GCST90003934 | 43.03 |
| 67 | Phospholipids to total lipids in very large HDL percentage (UKB data field 23629) | GCST90269726 | 42.48 |
| 68 | Cholesteryl ester levels in small HDL | GCST90092946 | 42.21 |
| 69 | APP/CCL28 ratio | GCST90313317 | 41.79 |
| 70 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502581 | 41.70 |
| 71 | Phospholipids in small HDL | GCST90499483 | 41.64 |
| 72 | IDP dMRI TBSS L2 Posterior limb of internal capsule R | GCST90004141 | 41.46 |
| 73 | Cholesteryl esters to total lipids in large VLDL percentage (UKB data field 23591) | GCST90269688 | 41.39 |
| 74 | Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093045 | 41.38 |
| 75 | GPIHBP1 levels | GCST90469390 | 41.31 |
| 76 | BMP4 levels | GCST90468453 | 41.29 |
| 77 | IL31RA levels | GCST90469589 | 40.60 |
| 78 | CNTN1/EGFR ratio | GCST90314162 | 40.46 |
| 79 | GFER/TRIAP1 ratio | GCST90314921 | 40.16 |
| 80 | PRCP/SELE ratio | GCST90315726 | 39.90 |
| 81 | SIRPA levels | GCST90470639 | 39.81 |
| 82 | Triglycerides in very large VLDL | GCST90500680 | 39.70 |
| 83 | Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587) | GCST90269684 | 39.60 |
| 84 | Free cholesterol in very large HDL | GCST90500380 | 39.58 |
| 85 | Omega-6 fatty acid levels | GCST90502100 | 39.53 |
| 86 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90500965 | 39.45 |
| 87 | Linoleic acid levels | GCST90498309 | 38.84 |
| 88 | PCDH17 levels | GCST90470169 | 38.82 |
| 89 | Osteoarthritis; localized | musculoskeletal | UKBB00000595 | 38.75 |
| 90 | Cholesterol levels in very large HDL | GCST90500310 | 38.46 |
| 91 | Main speciality of consultant (recoded) - Gastroenterology | Summary Administration | UKBB00000415 | 38.23 |
| 92 | Phospholipids to total lipids ratio in medium LDL | GCST90092913 | 38.20 |
| 93 | HippSubfield lh volume hippocampal-fissure | GCST90002672 | 38.04 |
| 94 | CRELD2/HYOU1 ratio | GCST90314255 | 38.03 |
| 95 | Phospholipids to total lipids ratio in large LDL | GCST90092865 | 38.00 |
| 96 | DAB2/TBL1X ratio | GCST90314368 | 37.91 |
| 97 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90500905 | 37.72 |
| 98 | Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585) | GCST90269682 | 37.57 |
| 99 | Free cholesterol in medium VLDL | GCST90498965 | 37.46 |
| 100 | Phosphatidylglycerol (34:1) levels | GCST90025061 | 37.45 |
| 101 | Chronic ulcer of leg or foot (PheCode 707.2) | GCST90476218 | 37.18 |
| 102 | CNTN1 levels | GCST90468803 | 37.06 |
| 103 | Cholesterol in Small HDL | GCST90499358 | 37.01 |
| 104 | Phospholipids in medium VLDL | GCST90499024 | 36.60 |
| 105 | Cholesterol to total lipids in small HDL percentage (UKB data field 23645) | GCST90269742 | 36.48 |
| 106 | N-delta-acetylornithine levels | GCST90200691 | 36.43 |
| 107 | Phospholipids in HDL | GCST90497430 | 36.35 |
| 108 | Cholesteryl Esters in Large VLDL | GCST90498146 | 36.32 |
| 109 | DTI autoptx FA slf l tract | GCST90385133 | 36.05 |
| 110 | Linoleic acid to total fatty acids percentage | GCST90502320 | 35.97 |
| 111 | PLG levels | GCST90470257 | 35.96 |
| 112 | Phospholipids to total lipids in medium VLDL percentage (UKB data field 23594) | GCST90269691 | 35.95 |
| 113 | Linoleic acid to total fatty acids percentage | GCST90502332 | 35.94 |
| 114 | Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646) | GCST90269743 | 35.93 |
| 115 | Dimethylglycine levels | GCST90200424 | 35.88 |
| 116 | Average diameter for HDL particles | GCST90497454 | 35.69 |
| 117 | IDP dMRI TBSS MO Posterior limb of internal capsule R | GCST90003970 | 35.58 |
| 118 | AXIN1/CDKN1A ratio | GCST90313403 | 35.57 |
| 119 | MPHOSPH8/PSRC1 ratio | GCST90315478 | 35.29 |
| 120 | Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580) | GCST90269677 | 35.25 |
| 121 | Acetate levels (UKB data field 23475) | GCST90269572 | 35.16 |
| 122 | Concentration of medium HDL particles | GCST90498617 | 35.13 |
| 123 | Phospholipids to total lipids in large VLDL percentage (UKB data field 23589) | GCST90269686 | 35.09 |
| 124 | Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631) | GCST90269728 | 35.03 |
| 125 | IDP dMRI ProbtrackX L2 cst r | GCST90004282 | 34.92 |
| 126 | Biological Grandparent (paternal): Coronary Artery / Coronary Heart Disease | GCST90475548 | 34.65 |
| 127 | Docosahexaenoic acid levels | GCST90501984 | 34.55 |
| 128 | Phospholipids in HDL | GCST90497437 | 34.31 |
| 129 | Free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23582) | GCST90269679 | 34.18 |
| 130 | Docosahexaenoic acid levels | GCST90502242 | 34.06 |
| 131 | Triglycerides in medium LDL | GCST90498870 | 34.00 |
| 132 | Total lipids in medium HDL | GCST90498597 | 33.99 |
| 133 | Omega-6 fatty acids to total fatty acids percentage | GCST90502540 | 33.99 |
| 134 | AXIN1/INPPL1 ratio | GCST90313410 | 33.92 |
| 135 | Phospholipids in very large HDL | GCST90500451 | 33.88 |
| 136 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502075 | 33.87 |
| 137 | NCF2 levels | GCST90470006 | 33.74 |
| 138 | Omega-3 fatty acid levels | GCST90502062 | 33.69 |
| 139 | IDP dMRI ProbtrackX L3 cst r | GCST90004309 | 33.68 |
| 140 | Triglycerides to total lipids in large VLDL percentage (UKB data field 23593) | GCST90269690 | 33.65 |
| 141 | Phospholipids in large HDL | GCST90497847 | 33.43 |
| 142 | Free cholesterol in very large VLDL | GCST90500575 | 33.39 |
| 143 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502166 | 33.35 |
| 144 | CTSB levels | GCST90468908 | 33.34 |
| 145 | SLC39A5 levels | GCST90470661 | 33.32 |
| 146 | Free cholesterol in very large HDL | GCST90500383 | 33.26 |
| 147 | Ratio of docosahexaenoic acid to total fatty acid levels | GCST90092817 | 33.12 |
| 148 | Free cholesterol to total lipids ratio in large VLDL | GCST90092873 | 33.09 |
| 149 | Cholesterol to total lipids ratio in large VLDL | GCST90092869 | 33.07 |
| 150 | OXT levels | GCST90470139 | 33.03 |
| 151 | CRKL/PLA2G4A ratio | GCST90314271 | 32.91 |
| 152 | Other predominantly sexually transmitted diseases, not elsewhere classified | FING00001089 | 32.76 |
| 153 | Phospholipids in large LDL | GCST90498049 | 32.74 |
| 154 | Phospholipids to Total Lipids in Medium HDL percentage | GCST90498651 | 32.57 |
| 155 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498580 | 32.54 |
| 156 | Free cholesterol in very large VLDL | GCST90500581 | 32.52 |
| 157 | Cholesterol_[M+H-H2O]1+ levels | GCST90060133 | 32.51 |
| 158 | CLEC4G/SEMA3F ratio | GCST90314123 | 32.44 |
| 159 | ERBB2/FURIN ratio | GCST90314686 | 32.41 |
| 160 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498583 | 32.40 |
| 161 | Saturated fatty acids levels | GCST90499950 | 32.39 |
| 162 | Phospholipids to Total Lipids in Medium HDL percentage | GCST90498653 | 32.29 |
| 163 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502644 | 32.05 |
| 164 | ING1 levels | GCST90469613 | 32.03 |
| 165 | Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453) | GCST90269550 | 31.91 |
| 166 | Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452) | GCST90269549 | 31.90 |
| 167 | BCAN/NCAN ratio | GCST90313481 | 31.79 |
| 168 | Cholesterol to total lipids in small VLDL percentage (UKB data field 23600) | GCST90269697 | 31.77 |
| 169 | Fasting blood glucose | GCST000568 | 31.71 |
| 170 | PLTP levels | GCST90470262 | 31.69 |
| 171 | Triglycerides to total lipids ratio in medium LDL | GCST90092915 | 31.62 |
| 172 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502592 | 31.24 |
| 173 | AMBP/EFEMP1 ratio | GCST90313253 | 31.12 |
| 174 | Triglycerides in very large VLDL | GCST90500671 | 31.03 |
| 175 | Phospholipids to total lipids in small HDL percentage (UKB data field 23644) | GCST90269741 | 30.85 |
| 176 | Cholesteryl Esters in Small VLDL | GCST90499782 | 30.84 |
| 177 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90500943 | 30.61 |
| 178 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90501042 | 30.51 |
| 179 | Omega-6 fatty acids to total fatty acids percentage | GCST90502121 | 30.50 |
| 180 | ITGAV levels | GCST90469639 | 30.40 |
| 181 | APOA1 levels | GCST90497119 | 30.35 |
| 182 | DTI TBSS FA Superior longitudinal fasciculus L | GCST90384421 | 30.24 |
| 183 | aparc-pial rh area lateraloccipital | GCST90003184 | 30.21 |
| 184 | Acetate levels | GCST90092803 | 30.08 |
| 185 | Fasting plasma glucose | GCST90297787 | 30.07 |
| 186 | Ratio of saturated fatty acids to total fatty acids | GCST90092981 | 30.01 |
| 187 | Triglycerides in medium VLDL | GCST90499065 | 29.91 |
| 188 | Cholesterol in Medium VLDL | GCST90498903 | 29.87 |
| 189 | Free cholesterol to total lipids in small LDL percentage (UKB data field 23627) | GCST90269724 | 29.79 |
| 190 | ENG/PEAR1 ratio | GCST90314649 | 29.68 |
| 191 | Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597) | GCST90269694 | 29.65 |
| 192 | AXIN1/MAP2K6 ratio | GCST90313413 | 29.58 |
| 193 | Phospholipids in small HDL | GCST90499478 | 29.58 |
| 194 | APOM/MCAM ratio | GCST90313315 | 29.57 |
| 195 | DTI autoptx FA slf r tract | GCST90385134 | 29.41 |
| 196 | Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093041 | 29.40 |
| 197 | Total lipids in medium HDL | GCST90498604 | 29.39 |
| 198 | Estradiol levels | GCST90012105 | 29.34 |
| 199 | Past tobacco smoking | Smoking | UKBB00000635 | 29.31 |
| 200 | Concentration of medium HDL particles | GCST90498622 | 29.29 |
| 201 | AXIN1/CALCOCO1 ratio | GCST90313402 | 29.10 |
| 202 | Tiglylcarnitine (C5:1-DC) levels | GCST90199800 | 29.09 |
| 203 | Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605) | GCST90269702 | 29.00 |
| 204 | Free cholesterol in very small VLDL | GCST90500774 | 29.00 |
| 205 | CLU levels | GCST90468793 | 28.98 |
| 206 | NCR1 levels | GCST90090153 | 28.94 |
| 207 | Cholesterol levels in very large HDL | GCST90500322 | 28.93 |
| 208 | MXRA8 levels | GCST90469968 | 28.90 |
| 209 | Free cholesterol in IDL | GCST90497561 | 28.87 |
| 210 | Triglycerides to total lipids in small VLDL percentage (UKB data field 23603) | GCST90269700 | 28.83 |
| 211 | Cholesterol in Large VLDL | GCST90498119 | 28.71 |
| 212 | Total Lipids in HDL | GCST90497401 | 28.66 |
| 213 | Free cholesterol to total lipids ratio in very large VLDL | GCST90093021 | 28.66 |
| 214 | Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608) | GCST90269705 | 28.61 |
| 215 | Phospholipids to total lipids ratio in very small VLDL | GCST90093037 | 28.61 |
| 216 | Phosphatidylinositol (20:0_20:4) levels | GCST90025083 | 28.50 |
| 217 | Saturated fatty acids to total fatty acids percentage | GCST90502696 | 28.46 |
| 218 | Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602) | GCST90269699 | 28.33 |
| 219 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502399 | 28.25 |
| 220 | Linoleic acid levels | GCST90502009 | 28.23 |
| 221 | NRP1 levels | GCST90470085 | 28.17 |
| 222 | Phospholipids to Total Lipids in Very Large HDL percentage | GCST90500474 | 28.09 |
| 223 | Type 2 diabetes | GCST90468151 | 27.95 |
| 224 | Phospholipid levels in very large HDL | GCST90093012 | 27.87 |
| 225 | CKAP4/IL4R ratio | GCST90314072 | 27.84 |
| 226 | FST levels | GCST90012080 | 27.81 |
| 227 | Docosahexaenoic acid levels | GCST90502254 | 27.78 |
| 228 | Fresh fruit consumption | GCST90132979 | 27.69 |
| 229 | Cholesteryl esters to total lipids in very small VLDL percentage (UKB data field 23606) | GCST90269703 | 27.60 |
| 230 | PDCD5 levels | GCST90470182 | 27.57 |
| 231 | Cholesteryl Esters in Medium VLDL | GCST90498939 | 27.52 |
| 232 | TNC/VCAM1 ratio | GCST90315927 | 27.49 |
| 233 | IDP dMRI TBSS MO Posterior limb of internal capsule L | GCST90003971 | 27.32 |
| 234 | Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598) | GCST90269695 | 27.29 |
| 235 | CLEC1A/GPR37 ratio | GCST90314084 | 27.26 |
| 236 | Phospholipids in medium VLDL | GCST90499025 | 27.25 |
| 237 | Phospholipids in very large HDL | GCST90500458 | 27.23 |
| 238 | CLEC4A levels | GCST90468771 | 27.14 |
| 239 | Free cholesterol in medium VLDL | GCST90498960 | 27.09 |
| 240 | Total Lipids in HDL | GCST90497393 | 27.00 |
| 241 | Total lipids in very large HDL | GCST90500410 | 26.99 |
| 242 | Cholesteryl Esters to Total Lipids in Large HDL percentage | GCST90497763 | 26.98 |
| 243 | APOA1 levels | GCST90497122 | 26.94 |
| 244 | Triglycerides in medium LDL | GCST90498864 | 26.93 |
| 245 | ECE1 levels | GCST90469061 | 26.90 |
| 246 | IDP dMRI TBSS L2 Posterior limb of internal capsule L | GCST90004142 | 26.89 |
| 247 | CDON levels | GCST90468687 | 26.89 |
| 248 | FADD/NCK2 ratio | GCST90314770 | 26.77 |
| 249 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90501031 | 26.64 |
| 250 | Docosahexaenoic acid levels | GCST90501978 | 26.64 |
| 251 | LGALS1/LGALS8 ratio | GCST90315314 | 26.64 |
| 252 | IL1R2 levels | GCST90469572 | 26.45 |
| 253 | LTBP2/PDGFRA ratio | GCST90315338 | 26.45 |
| 254 | EGFR/FAP ratio | GCST90314613 | 26.41 |
| 255 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497863 | 26.38 |
| 256 | PLAUR/TREM2 ratio | GCST90315676 | 26.36 |
| 257 | SCARA5/TNC ratio | GCST90315810 | 26.33 |
| 258 | Cholesterol to Total Lipids in Medium HDL percentage | GCST90498519 | 26.28 |
| 259 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497793 | 26.26 |
| 260 | Concentration of very large HDL particles | GCST90500436 | 26.26 |
| 261 | Triglycerides to total lipids ratio in very large VLDL | GCST90093027 | 26.25 |
| 262 | Docosahexaenoic acid levels (UKB data field 23450) | GCST90269547 | 26.20 |
| 263 | Phosphoglycerides levels | GCST90499259 | 26.19 |
| 264 | Cholesteryl esters to total lipids ratio in large VLDL | GCST90092871 | 26.17 |
| 265 | Average diameter for HDL particles | GCST90132702 | 26.07 |
| 266 | Chronic hepatitis C infection | GCST90018585 | 26.04 |
| 267 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90501075 | 26.03 |
| 268 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502411 | 26.01 |
| 269 | LGALS3 levels | GCST90469761 | 25.95 |
| 270 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502173 | 25.93 |
| 271 | PROC levels | GCST90470335 | 25.89 |
| 272 | RAD23B levels | GCST90470418 | 25.85 |
| 273 | CNPY4/STAT5B ratio | GCST90314155 | 25.77 |
| 274 | Cholesterol to Total Lipids in Large HDL percentage | GCST90497730 | 25.72 |
| 275 | FLT1/TGFB1 ratio | GCST90314857 | 25.63 |
| 276 | DKKL1 levels | GCST90469000 | 25.57 |
| 277 | F9/PROC ratio | GCST90314748 | 25.57 |
| 278 | Iritis | GCST90018651 | 25.53 |
| 279 | LRP1 levels | GCST90469797 | 25.53 |
| 280 | Triglycerides in small LDL | GCST90499712 | 25.51 |
| 281 | ENG/TNFSF10 ratio | GCST90314651 | 25.51 |
| 282 | Cholesterol to total lipids ratio in very large HDL | GCST90093005 | 25.49 |
| 283 | Chronic ulcer of skin (PheCode 707) | GCST90476216 | 25.45 |
| 284 | Osteoarthritis | GCST90476383 | 25.42 |
| 285 | Otosclerosis | FING00001131 | 25.34 |
| 286 | Cholesteryl Esters in IDL | GCST90497523 | 25.27 |
| 287 | Cholesterol to total lipids in large LDL percentage (UKB data field 23615) | GCST90269712 | 25.26 |
| 288 | CLPP/DECR1 ratio | GCST90314137 | 25.24 |
| 289 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502566 | 25.22 |
| 290 | Average diameter for HDL particles | GCST90092828 | 25.14 |
| 291 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458) | GCST90269555 | 25.12 |
| 292 | ERP44 levels | GCST90469150 | 25.11 |
| 293 | TFRC levels | GCST90451684 | 25.04 |
| 294 | ATXN10/CASP10 ratio | GCST90313396 | 25.02 |
| 295 | Triglycerides to total lipids ratio in large LDL | GCST90092867 | 25.00 |
| 296 | Average diameter for HDL particles (UKB data field 23433) | GCST90269530 | 24.92 |
| 297 | CC2D1A/STIP1 ratio | GCST90313665 | 24.91 |
| 298 | Omega-6 fatty acids to total fatty acids percentage | GCST90502127 | 24.86 |
| 299 | Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487) | GCST90269584 | 24.85 |
| 300 | MFAP4 levels | GCST90469898 | 24.84 |
| 301 | Lysophosphatidylethanolamine-P_20:0_[M-H]1- levels | GCST90060147 | 24.79 |
| 302 | Free Cholesterol in HDL | GCST90497381 | 24.78 |
| 303 | Cholesterol in Small VLDL | GCST90499746 | 24.76 |
| 304 | Docosahexaenoic acid to total fatty acids percentage | GCST90502281 | 24.76 |
| 305 | Triglycerides in LDL (UKB data field 23409) | GCST90269506 | 24.73 |
| 306 | Concentration of HDL particles | GCST90497414 | 24.72 |
| 307 | Cholesteryl esters to total lipids ratio in small VLDL | GCST90092971 | 24.72 |
| 308 | Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500324 | 24.68 |
| 309 | DNAJB1/STIP1 ratio | GCST90314513 | 24.65 |
| 310 | Ratio of polyunsaturated fatty acids to total fatty acids | GCST90092941 | 24.61 |
| 311 | Cholesteryl Esters to Total Lipids in Medium HDL percentage | GCST90498550 | 24.55 |
| 312 | Sleep apnea syndrome | GCST90267361 | 24.52 |
| 313 | Fasting blood insulin | GCST005185 | 24.48 |
| 314 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500359 | 24.44 |
| 315 | LAT2/SERPINB1 ratio | GCST90315279 | 24.39 |
| 316 | NTRK2 levels | GCST90470097 | 24.39 |
| 317 | IDP dMRI TBSS FA Superior cerebellar peduncle R | GCST90003889 | 24.38 |
| 318 | Cholesterol in Medium LDL | GCST90498703 | 24.38 |
| 319 | Cholesterol levels in small HDL | GCST90092944 | 24.31 |
| 320 | Arabitol/xylitol levels | GCST90200011 | 24.18 |
| 321 | Triacylglycerol_56:5_[M+NH4]1+ levels | GCST90060554 | 24.18 |
| 322 | Free cholesterol to total lipids ratio in very large HDL | GCST90093009 | 24.17 |
| 323 | HNRNPAB levels | GCST90088693 | 24.16 |
| 324 | Total cholesterol levels | GCST90239675 | 24.14 |
| 325 | Total lipids in large HDL | GCST90497815 | 24.11 |
| 326 | Triglycerides to Total Lipids in Large HDL percentage | GCST90497896 | 24.01 |
| 327 | Breast conditions, congenital or relating to hormones (PheCode 612) | GCST90476162 | 24.00 |
| 328 | AIFM1/PLXNA4 ratio | GCST90313220 | 23.99 |
| 329 | Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595) | GCST90269692 | 23.98 |
| 330 | Phospholipids to total lipids in IDL percentage (UKB data field 23609) | GCST90269706 | 23.98 |
| 331 | Triglycerides to total lipids ratio in IDL | GCST90092842 | 23.97 |
| 332 | Omega-3 fatty acid levels | GCST90502056 | 23.95 |
| 333 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497868 | 23.95 |
| 334 | CHL1 levels | GCST90468745 | 23.92 |
| 335 | MCAM levels | GCST90469870 | 23.90 |
| 336 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T83 | ECGA000083 | 23.90 |
| 337 | Blood cell traits latent factor 20 (red cell) | GCST90559262 | 23.89 |
| 338 | Polyunsaturated fatty acid levels | GCST90502133 | 23.84 |
| 339 | CNDP1/EGFR ratio | GCST90314146 | 23.82 |
| 340 | Cholesterol to total lipids in small LDL percentage (UKB data field 23625) | GCST90269722 | 23.82 |
| 341 | Free cholesterol in large HDL | GCST90497786 | 23.80 |
| 342 | GRAP2/PTPN6 ratio | GCST90314986 | 23.80 |
| 343 | ITGA5/SELE ratio | GCST90315205 | 23.72 |
| 344 | SERPINF2 levels | GCST90470599 | 23.67 |
| 345 | CCL28/PDGFB ratio | GCST90313695 | 23.67 |
| 346 | Osteoarthrosis | musculoskeletal | UKBB00000596 | 23.67 |
| 347 | Average diameter for VLDL particles (UKB data field 23431) | GCST90269528 | 23.66 |
| 348 | Concentration of large HDL particles | GCST90497828 | 23.63 |
| 349 | Posterior thigh muscle volume | GCST90267353 | 23.61 |
| 350 | Triglycerides to total lipids ratio in large VLDL | GCST90092879 | 23.59 |
| 351 | Phospholipids to total lipids ratio in IDL | GCST90092840 | 23.58 |
| 352 | Free Cholesterol in HDL | GCST90497379 | 23.54 |
| 353 | Metabolic syndrome | GCST009602 | 23.53 |
| 354 | Fresh fruit intake | Diet | UKBB00000272 | 23.50 |
| 355 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T84 | ECGA000084 | 23.48 |
| 356 | Concentration of very large HDL particles | GCST90500431 | 23.47 |
| 357 | Glutamine levels | GCST90092818 | 23.47 |
| 358 | Triglycerides in medium LDL (UKB data field 23543) | GCST90269640 | 23.47 |
| 359 | Phospholipids to total lipids ratio in medium VLDL | GCST90092925 | 23.41 |
| 360 | Phospholipids to total lipids in small VLDL percentage (UKB data field 23599) | GCST90269696 | 23.36 |
| 361 | NAAA/SMPD1 ratio | GCST90315510 | 23.36 |
| 362 | Free cholesterol in small HDL | GCST90499425 | 23.30 |
| 363 | Cholesteryl Esters in Small VLDL | GCST90499786 | 23.30 |
| 364 | ENPP5 levels | GCST90469116 | 23.28 |
| 365 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502179 | 23.26 |
| 366 | PDGFB/SPARC ratio | GCST90315628 | 23.24 |
| 367 | EREG/MPIG6B ratio | GCST90314704 | 23.23 |
| 368 | Concentration of small HDL particles | GCST90092951 | 23.17 |
| 369 | Phospholipids in very small VLDL | GCST90500840 | 23.15 |
| 370 | Phospholipids in medium LDL | GCST90498831 | 23.13 |
| 371 | Cholesteryl Esters to Total Lipids in Very Small VLDL percentage | GCST90500764 | 23.09 |
| 372 | Triglycerides in small VLDL | GCST90499917 | 23.03 |
| 373 | 1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels | GCST90200057 | 23.00 |
| 374 | Lysophosphatidylcholine_16:1_[M+H]1+/Lysophosphatidylethanolamine_19:1_[M+H]1+ levels | GCST90060148 | 23.00 |
| 375 | BCAM/PCDH17 ratio | GCST90313475 | 22.99 |
| 376 | HDL cholesterol levels | GCST90497352 | 22.95 |
| 377 | Linoleic acid to total fatty acids percentage | GCST90502023 | 22.93 |
| 378 | Phospholipids to total lipids ratio in small HDL | GCST90092953 | 22.90 |
| 379 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502069 | 22.89 |
| 380 | APOA levels | GCST90468061 | 22.89 |
| 381 | Right molecular layer hippocampal volume (body) | GCST90267975 | 22.80 |
| 382 | Phospholipids to total lipids in medium LDL percentage (UKB data field 23619) | GCST90269716 | 22.74 |
| 383 | DTI autoptx FA fmi tract | GCST90385123 | 22.71 |
| 384 | Cholesterol in Small LDL | GCST90499559 | 22.65 |
| 385 | Cholesterol levels in very large VLDL | GCST90500517 | 22.55 |
| 386 | Total cholines levels | GCST90497185 | 22.53 |
| 387 | DTI TBSS L3 Superior longitudinal fasciculus L | GCST90384565 | 22.52 |
| 388 | IDP dMRI ProbtrackX L2 cst l | GCST90004281 | 22.52 |
| 389 | high density lipoprotein cholesterol (HDLC, maximum, inv-norm transformed) | GCST90475348 | 22.52 |
| 390 | Triglycerides in large LDL | GCST90498083 | 22.51 |
| 391 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502398 | 22.51 |
| 392 | Weight-to-muscle ratio | GCST90267359 | 22.46 |
| 393 | Free cholesterol in large HDL | GCST90497780 | 22.45 |
| 394 | Grapefruit liking | GCST90094774 | 22.43 |
| 395 | APOA levels | UKBB00000040 | 22.40 |
| 396 | Cholesterol levels in very large VLDL | GCST90500518 | 22.36 |
| 397 | TIE1 levels | GCST90470863 | 22.34 |
| 398 | PAPPA levels | GCST90470157 | 22.33 |
| 399 | Total concentration of lipoprotein particles | GCST90500101 | 22.32 |
| 400 | Average diameter for LDL particles | GCST90498458 | 22.29 |
| 401 | Cholesterol in IDL | GCST90497495 | 22.27 |
| 402 | Cholesterol esters in very large HDL | GCST90500344 | 22.25 |
| 403 | Metabolic syndrome | GCST90444489 | 22.23 |
| 404 | Hippocampal subfield right CA1 volume (head) | GCST90267961 | 22.18 |
| 405 | CD99 levels | GCST90468658 | 22.18 |
| 406 | Omega-6 fatty acids levels | GCST90499177 | 22.13 |
| 407 | Cholesterol in Medium LDL | GCST90498707 | 22.11 |
| 408 | IFIT2 levels | GCST90090864 | 22.06 |
| 409 | APBB1IP/NADK ratio | GCST90313298 | 22.03 |
| 410 | IDP dMRI TBSS ICVF Uncinate fasciculus L | GCST90004372 | 21.99 |
| 411 | Cholesteryl esters in very large VLDL | GCST90500552 | 21.97 |
| 412 | Cholesterol to total lipids in very large HDL percentage (UKB data field 23630) | GCST90269727 | 21.97 |
| 413 | CCL22 levels | GCST90240490 | 21.90 |
| 414 | Docosahexaenoic acid to total fatty acids percentage | GCST90501997 | 21.88 |
| 415 | PRTG levels | GCST90470347 | 21.85 |
| 416 | aseg global volume 3rd-Ventricle | GCST90002599 | 21.77 |
| 417 | Free cholesterol in medium HDL | GCST90498562 | 21.73 |
| 418 | Free cholesterol in large VLDL | GCST90498181 | 21.70 |
| 419 | ADH4/DCXR ratio | GCST90313190 | 21.70 |
| 420 | Cholesteryl Esters in HDL | GCST90497368 | 21.65 |
| 421 | T1 FreeSurfer a2009s rh G&S subcentral volume | GCST90385041 | 21.64 |
| 422 | Smoking status - Never | Smoking | UKBB00000780 | 21.63 |
| 423 | IDP dMRI TBSS L2 Anterior limb of internal capsule L | GCST90004140 | 21.60 |
| 424 | Hearing difficulty and hearing difficulty with background noise | GCST90245776 | 21.59 |
| 425 | Average diameter for VLDL particles | GCST90500279 | 21.57 |
| 426 | Free cholesterol to total lipids in large LDL percentage (UKB data field 23617) | GCST90269714 | 21.56 |
| 427 | Mean diameter of VLDL particles | GCST90132734 | 21.55 |
| 428 | IDP dMRI TBSS OD Posterior limb of internal capsule L | GCST90004421 | 21.54 |
| 429 | Peripheral vascular disease | GCST90475219 | 21.54 |
| 430 | Phosphatidylcholine levels | GCST90499240 | 21.53 |
| 431 | Free cholesterol in large VLDL | GCST90498185 | 21.52 |
| 432 | Unspecified osteomyelitis (PheCode 710.19) | GCST90476224 | 21.48 |
| 433 | BAX levels | GCST90468424 | 21.47 |
| 434 | ADAM23 levels | GCST90468219 | 21.45 |
| 435 | Total lipid levels in very large HDL | GCST90093010 | 21.41 |
| 436 | Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632) | GCST90269729 | 21.40 |
| 437 | Phospholipids in small VLDL | GCST90499881 | 21.39 |
| 438 | Cholesterol to total lipids ratio in small HDL | GCST90092945 | 21.39 |
| 439 | Average diameter for LDL particles (UKB data field 23432) | GCST90269529 | 21.38 |
| 440 | KDR levels | GCST90469672 | 21.36 |
| 441 | Glutamine levels (UKB data field 23461) | GCST90269558 | 21.30 |
| 442 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502384 | 21.27 |
| 443 | Triglycerides in IDL | GCST90497661 | 21.25 |
| 444 | Docosahexaenoic acid to total fatty acids percentage | GCST90497268 | 21.23 |
| 445 | 1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels | GCST90200330 | 21.22 |
| 446 | STX8/USP8 ratio | GCST90315896 | 21.21 |
| 447 | Smoking status, ever vs never | Other measurement | UKBB00000782 | 21.21 |
| 448 | ISLR2 levels | GCST90469629 | 21.21 |
| 449 | Omega-3 fatty acid levels | GCST90502437 | 21.20 |
| 450 | Triglycerides in large LDL | GCST90498076 | 21.18 |
| 451 | Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596) | GCST90269693 | 21.15 |
| 452 | PTPRM/SELE ratio | GCST90315753 | 21.13 |
| 453 | STK24/TDRKH ratio | GCST90315893 | 21.12 |
| 454 | N-acetylalanine levels | GCST90200303 | 21.10 |
| 455 | Phospholipids in IDL | GCST90497628 | 21.07 |
| 456 | DTI autoptx MD ptr r tract | GCST90385240 | 21.06 |
| 457 | high density lipoprotein cholesterol (HDLC, minimm, inv-norm transformed) | GCST90475356 | 21.01 |
| 458 | DNAJB1/METAP2 ratio | GCST90314509 | 20.99 |
| 459 | Cholesterol to Total Lipids in Medium HDL percentage | GCST90498516 | 20.93 |
| 460 | NADK/PXN ratio | GCST90315512 | 20.91 |
| 461 | ANGPTL3/TFPI ratio | GCST90313270 | 20.83 |
| 462 | high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed) | GCST90475352 | 20.80 |
| 463 | Total lipids in large HDL | GCST90497818 | 20.77 |
| 464 | Docosahexaenoic acid to total fatty acids percentage | GCST90497270 | 20.74 |
| 465 | Phospholipids in large VLDL | GCST90498247 | 20.72 |
| 466 | Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622) | GCST90269719 | 20.68 |
| 467 | Average diameter for VLDL particles | GCST90093002 | 20.67 |
| 468 | Free cholesterol levels in very large HDL | GCST90132680 | 20.64 |
| 469 | MAMDC2 levels | GCST90469841 | 20.56 |
| 470 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502580 | 20.54 |
| 471 | Phospholipids in medium HDL (UKB data field 23567) | GCST90269664 | 20.50 |
| 472 | Red cell distribution width variance | GCST90565705 | 20.47 |
| 473 | IDP dMRI TBSS L2 Uncinate fasciculus L | GCST90004168 | 20.43 |
| 474 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500398 | 20.38 |
| 475 | ICD10 N84: Polyp of female genital tract | GCST90454216 | 20.37 |
| 476 | Docosahexaenoic acid to total fatty acids percentage | GCST90502268 | 20.35 |
| 477 | Degree of unsaturation | GCST90502736 | 20.33 |
| 478 | Triglycerides in large VLDL | GCST90498267 | 20.33 |
| 479 | Cholesteryl esters in very large VLDL | GCST90500556 | 20.32 |
| 480 | Free cholesterol in medium HDL | GCST90498563 | 20.26 |
| 481 | IDP dMRI ProbtrackX L3 cst l | GCST90004308 | 20.25 |
| 482 | BOC levels | GCST90468458 | 20.22 |
| 483 | Cholesterol in IDL | GCST90497501 | 20.20 |
| 484 | Free cholesterol in small VLDL | GCST90499808 | 20.17 |
| 485 | RBP7 levels | GCST90470440 | 20.17 |
| 486 | aparc-DKTatlas rh area lateraloccipital | GCST90003274 | 20.12 |
| 487 | Free cholesterol to total lipids ratio in medium VLDL | GCST90092921 | 20.11 |
| 488 | FLRT2/GFRA3 ratio | GCST90314855 | 20.11 |
| 489 | CD200/CLEC4G ratio | GCST90313746 | 20.09 |
| 490 | SERPINA5 levels | GCST90470585 | 20.08 |
| 491 | Phospholipids to Total Lipids in Very Large HDL percentage | GCST90500472 | 20.04 |
| 492 | DTI autoptx L3 slf l tract | GCST90385214 | 20.03 |
| 493 | Hypotaurine levels | GCST90200379 | 20.02 |
| 494 | Cholesterol in Small HDL | GCST90499348 | 20.02 |
| 495 | Average diameter for HDL particles | GCST90497446 | 19.98 |
| 496 | High-density lipoprotein levels (MTAG) | GCST90179147 | 19.96 |
| 497 | Ovarian cancer-related tumor marker CA 125 levels | GCST90012078 | 19.95 |
| 498 | PTPN1/TDRKH ratio | GCST90315745 | 19.89 |
| 499 | ADAMTSL4 levels | GCST90468229 | 19.89 |
| 500 | Free cholesterol levels in very large HDL | GCST90093008 | 19.88 |
| 501 | NUDT5/TXNRD1 ratio | GCST90315582 | 19.77 |
| 502 | SEMA3F levels | GCST90470570 | 19.73 |
| 503 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 64) | GCST90320627 | 19.69 |
| 504 | HAVCR2/TREM2 ratio | GCST90315031 | 19.66 |
| 505 | CDCP1/MSR1 ratio | GCST90313938 | 19.66 |
| 506 | PEAR1 levels | GCST90470204 | 19.62 |
| 507 | Phospholipids in large HDL (UKB data field 23560) | GCST90269657 | 19.60 |
| 508 | Levulinate 4-oxovalerate levels | GCST90243545 | 19.58 |
| 509 | aparc-a2009s lh volume S-central | GCST90002969 | 19.56 |
| 510 | Phospholipids to total lipids ratio in large VLDL | GCST90092877 | 19.56 |
| 511 | Triglycerides in IDL | GCST90497671 | 19.55 |
| 512 | Cholesteryl esters in small HDL (UKB data field 23576) | GCST90269673 | 19.55 |
| 513 | BA-exvivo lh volume BA4p | GCST90002840 | 19.55 |
| 514 | MAPK9 levels | GCST90469857 | 19.54 |
| 515 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502633 | 19.53 |
| 516 | Phospholipid levels in medium HDL | GCST90092900 | 19.53 |
| 517 | IDP dMRI ProbtrackX FA cst l | GCST90003933 | 19.51 |
| 518 | IDP dMRI TBSS ICVF Cerebral peduncle R | GCST90004341 | 19.50 |
| 519 | Docosahexaenoic acid to total fatty acids percentage | GCST90501991 | 19.47 |
| 520 | Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500731 | 19.44 |
| 521 | Concentration of medium HDL particles (UKB data field 23565) | GCST90269662 | 19.43 |
| 522 | Abdominal and pelvic pain | Symptoms and signs involving the digestive system and abdomen | UKBB00000001 | 19.43 |
| 523 | CRADD/DARS1 ratio | GCST90314234 | 19.40 |
| 524 | Substance dependence | GCST90018704 | 19.39 |
| 525 | Concentration of HDL particles | GCST90497406 | 19.36 |
| 526 | Free cholesterol in medium HDL (UKB data field 23570) | GCST90269667 | 19.34 |
| 527 | CDH6 levels | GCST90468677 | 19.31 |
| 528 | Phospholipid levels in large HDL | GCST90092852 | 19.31 |
| 529 | APOA1 levels | GCST90269537 | 19.30 |
| 530 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501092 | 19.29 |
| 531 | Triglycerides in medium VLDL | GCST90499064 | 19.23 |
| 532 | Average diameter for LDL particles | GCST90498457 | 19.22 |
| 533 | Sleep apnea | neurological | UKBB00000774 | 19.18 |
| 534 | COX5B levels | GCST90468834 | 19.15 |
| 535 | NOTCH3 levels | GCST90470067 | 19.10 |
| 536 | Docosahexaenoic acid to total fatty acids percentage | GCST90502280 | 19.09 |
| 537 | Degree of unsaturation | GCST90502231 | 19.08 |
| 538 | Cholesterol in Medium VLDL | GCST90498909 | 19.08 |
| 539 | Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels | GCST90060254 | 19.07 |
| 540 | Triglycerides in large LDL (UKB data field 23536) | GCST90269633 | 19.04 |
| 541 | 3-hydroxydecanoate metabolite level | GCST90615472 | 19.03 |
| 542 | PARK7 levels | GCST90470159 | 19.01 |
| 543 | ARF6 levels | GCST90468348 | 19.01 |
| 544 | DAPP1/PTPN6 ratio | GCST90314397 | 19.00 |
| 545 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T254 | ECGU000254 | 18.98 |
| 546 | CLEC4G/MERTK ratio | GCST90314121 | 18.97 |
| 547 | Worry too long after embarrassment | Mental health | UKBB00000922 | 18.95 |
| 548 | Triglycerides in IDL (UKB data field 23529) | GCST90269626 | 18.92 |
| 549 | Triglycerides to total lipids ratio in small LDL | GCST90092967 | 18.91 |
| 550 | Cholesteryl Esters to Total Lipids in Medium HDL percentage | GCST90498556 | 18.91 |
| 551 | STAB2 levels | GCST90470755 | 18.90 |
| 552 | Concentration of large HDL particles | GCST90497836 | 18.89 |
| 553 | Triglycerides in very small VLDL (UKB data field 23522) | GCST90269619 | 18.85 |
| 554 | PCDH17/PTPRM ratio | GCST90315603 | 18.80 |
| 555 | Linoleic acid to total fatty acids percentage | GCST90502333 | 18.80 |
| 556 | Non-HDL cholesterol levels | GCST90239669 | 18.79 |
| 557 | IDP dMRI TBSS FA Middle cerebellar peduncle | GCST90003877 | 18.70 |
| 558 | CD40LG/EREG ratio | GCST90313820 | 18.69 |
| 559 | BCR/CLIP2 ratio | GCST90313486 | 18.69 |
| 560 | aparc-Desikan rh area lateraloccipital | GCST90003117 | 18.66 |
| 561 | Aneurysm of iliac artery (PheCode 442.2) | GCST90475995 | 18.63 |
| 562 | Osteomyelitis | FING00000911 | 18.63 |
| 563 | Glucosamine medication | FING00000584 | 18.60 |
| 564 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T255 | ECGU000255 | 18.53 |
| 565 | Phospholipids in large VLDL | GCST90498243 | 18.53 |
| 566 | Saturated fatty acids to total fatty acids percentage (UKB data field 23455) | GCST90269552 | 18.51 |
| 567 | NOTCH1/TIE1 ratio | GCST90315546 | 18.46 |
| 568 | Total cholesterol levels | GCST90018754 | 18.45 |
| 569 | CELA3A/CPA1 ratio | GCST90314009 | 18.42 |
| 570 | Autorefraction - 3mm cylindrical power (left) | Eyesight | UKBB00000062 | 18.41 |
| 571 | HDL cholesterol levels | GCST90497340 | 18.39 |
| 572 | AGRP/CCN1 ratio | GCST90313202 | 18.39 |
| 573 | DNAJB1 levels | GCST90469012 | 18.38 |
| 574 | Ectopic pregnancy | FING00000487 | 18.37 |
| 575 | GALNT10/TNFSF12 ratio | GCST90314916 | 18.36 |
| 576 | AXIN1/IKBKG ratio | GCST90313409 | 18.35 |
| 577 | Blood cell traits latent factor 4 (red cell) | GCST90559246 | 18.34 |
| 578 | Phosphatidylcholine_33:4_[M+H]1+/Phosphatidylethanolamine_36:4_[M+H]1+/Phosphatidate_38:5_[M+NH4]1+ levels | GCST90060273 | 18.30 |
| 579 | Parental longevity (both parents in top 10%) | GCST006698 | 18.30 |
| 580 | Triglycerides to total lipids ratio in medium VLDL | GCST90092927 | 18.28 |
| 581 | IDP dMRI TBSS ICVF External capsule L | GCST90004360 | 18.27 |
| 582 | Triglycerides | GCST002216 | 18.26 |
| 583 | TARBP2/TDRKH ratio | GCST90315902 | 18.26 |
| 584 | CTSC levels | GCST90468909 | 18.21 |
| 585 | EGF/MGLL ratio | GCST90314610 | 18.20 |
| 586 | Docosahexaenoic acid levels | GCST90497256 | 18.18 |
| 587 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502410 | 18.17 |
| 588 | ESAM/TGFB1 ratio | GCST90314718 | 18.17 |
| 589 | Omega-3 fatty acids to total fatty acids percentage | GCST90499155 | 18.15 |
| 590 | Medication use (HMG CoA reductase inhibitors) | GCST90018769 | 18.13 |
| 591 | EFNA4/LAYN ratio | GCST90314602 | 18.12 |
| 592 | LEFTY2 levels | GCST90469752 | 18.10 |
| 593 | Omega-6 fatty acids to total fatty acids percentage | GCST90502528 | 18.09 |
| 594 | Triglycerides to Total Lipids in Large HDL percentage | GCST90497906 | 18.06 |
| 595 | VPS37A levels | GCST90471046 | 18.03 |
| 596 | FADD/PLIN3 ratio | GCST90314772 | 18.03 |
| 597 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497790 | 18.02 |
| 598 | Total lipids in HDL (UKB data field 23426) | GCST90269523 | 17.99 |
| 599 | Cholesterol to total lipids ratio in small LDL | GCST90092957 | 17.97 |
| 600 | CCL18/TFPI ratio | GCST90313691 | 17.92 |
| 601 | BCAM levels | GCST90468425 | 17.91 |
| 602 | Free cholesterol in small LDL | GCST90499617 | 17.87 |
| 603 | Free cholesterol levels in medium HDL | GCST90092896 | 17.84 |
| 604 | QC rfMRI-to-T1 linear alignment discrepancy | GCST90006353 | 17.84 |
| 605 | Concentration of very large HDL particles | GCST90093011 | 17.83 |
| 606 | Phospholipids in large LDL | GCST90498053 | 17.82 |
| 607 | Total lipids in medium HDL (UKB data field 23566) | GCST90269663 | 17.80 |
| 608 | Saturated fatty acids to total fatty acids percentage | GCST90502684 | 17.78 |
| 609 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502632 | 17.76 |
| 610 | HDL x anxiety interaction (2df test) | GCST90570665 | 17.75 |
| 611 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500506 | 17.75 |
| 612 | Saturated fatty acids levels | GCST90499953 | 17.74 |
| 613 | Sphingomyelin_36:2_[M+H]1+ levels | GCST90060263 | 17.72 |
| 614 | Triglycerides in very large HDL (UKB data field 23557) | GCST90269654 | 17.70 |
| 615 | CREG1/NAAA ratio | GCST90314250 | 17.70 |
| 616 | SHMT1 levels | GCST90470627 | 17.70 |
| 617 | Phospholipids in HDL (UKB data field 23414) | GCST90269511 | 17.68 |
| 618 | Total lipids in very large HDL | GCST90500423 | 17.66 |
| 619 | GLB1/PCSK9 ratio | GCST90314933 | 17.66 |
| 620 | PSME2/RBKS ratio | GCST90315737 | 17.66 |
| 621 | CD80 levels | GCST90468650 | 17.64 |
| 622 | DTI TBSS MD Sagittal stratum L | GCST90384603 | 17.63 |
| 623 | Cholelithiasis and cholecystitis | digestive | UKBB00000133 | 17.60 |
| 624 | SUGT1/TBL1X ratio | GCST90315897 | 17.58 |
| 625 | FAP levels | GCST90469189 | 17.53 |
| 626 | Cholesterol to total lipids ratio in very large VLDL | GCST90093017 | 17.44 |
| 627 | Right-hemisphere control network to putamen white-matter structural connectivity | GCST90302838 | 17.40 |
| 628 | Phospholipids in very large HDL (UKB data field 23553) | GCST90269650 | 17.38 |
| 629 | CCDC80/CCL27 ratio | GCST90313669 | 17.37 |
| 630 | Total lipids in large HDL (UKB data field 23559) | GCST90269656 | 17.31 |
| 631 | CD69/SCARF1 ratio | GCST90313885 | 17.31 |
| 632 | Total lipid levels in medium HDL | GCST90092898 | 17.29 |
| 633 | APRT/MIF ratio | GCST90313336 | 17.29 |
| 634 | TNXB levels | GCST90470930 | 17.27 |
| 635 | Cholesterol in Large LDL | GCST90497923 | 17.26 |
| 636 | Cholesteryl esters to total lipids ratio in very large VLDL | GCST90093019 | 17.26 |
| 637 | Hearing difficulty | GCST90245774 | 17.26 |
| 638 | Phosphatidylcholine (34:5) levels | GCST90024286 | 17.24 |
| 639 | Ratio of omega-6 fatty acids to total fatty acids | GCST90092935 | 17.23 |
| 640 | Cholesterol in Small VLDL | GCST90499750 | 17.17 |
| 641 | Free cholesterol to total lipids ratio in large HDL | GCST90092849 | 17.16 |
| 642 | Phospholipids in very small VLDL | GCST90500851 | 17.15 |
| 643 | DCTN6/TDRKH ratio | GCST90314436 | 17.14 |
| 644 | Illnesses of siblings - Heart disease | Family history | UKBB00000351 | 17.13 |
| 645 | BCAM/NOTCH1 ratio | GCST90313474 | 17.12 |
| 646 | Triglyceride to HDL cholesterol ratio | GCST90295951 | 17.12 |
| 647 | Isoleucine levels | GCST90092843 | 17.04 |
| 648 | Sphingomyelin_42:2_[M+OAc]1- levels | GCST90060507 | 17.02 |
| 649 | Phospholipid levels in HDL | GCST90092827 | 17.02 |
| 650 | Omega-6 fatty acids to total fatty acids percentage | GCST90502529 | 16.99 |
| 651 | Saturated fatty acids to total fatty acids percentage | GCST90502697 | 16.97 |
| 652 | aseg rh intensity Lateral-Ventricle | GCST90003778 | 16.92 |
| 653 | CHMP1A levels | GCST90468746 | 16.88 |
| 654 | Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482) | GCST90269579 | 16.85 |
| 655 | Abdominal aortic aneurysm (PheCode 442.11) | GCST90475994 | 16.84 |
| 656 | ESAM/THPO ratio | GCST90314719 | 16.82 |
| 657 | Average diameter for LDL particles | GCST90092889 | 16.81 |
| 658 | BCL2L15 levels | GCST90468431 | 16.81 |
| 659 | IDP dMRI TBSS L3 External capsule L | GCST90004204 | 16.80 |
| 660 | Total phospholipid levels in lipoprotein particles | GCST90500110 | 16.79 |
| 661 | Total Phosphatidylcholine levels | GCST90025204 | 16.75 |
| 662 | Neuroticism score | Mental health | UKBB00000496 | 16.75 |
| 663 | Phosphatidylcholine_36:5_[M+H]1+/Phosphatidylethanolamine_39:5_[M+H]1+/Phosphatidate_41:6_[M+NH4]1+ levels | GCST90060345 | 16.73 |
| 664 | aparc-a2009s lh volume G-precentral | GCST90002953 | 16.72 |
| 665 | Omega-3 fatty acid levels | GCST90502424 | 16.71 |
| 666 | Cholesteryl esters to total lipids ratio in very large HDL | GCST90093007 | 16.68 |
| 667 | Liver proton density fat fraction | GCST90267352 | 16.64 |
| 668 | Cholesteryl esters in large HDL (UKB data field 23562) | GCST90269659 | 16.63 |
| 669 | Coxarthrosis [arthrosis of hip] | Arthrosis | UKBB00000154 | 16.63 |
| 670 | Saturated fatty acids levels | GCST90502192 | 16.62 |
| 671 | Cholesterol to total lipids ratio in medium VLDL | GCST90092917 | 16.61 |
| 672 | Lysophosphatidylcholine (22:6) [sn2] levels | GCST90024185 | 16.60 |
| 673 | HippSubfield lh volume molecular-layer-HP-head | GCST90002677 | 16.55 |
| 674 | Colorectal cancer | GCST90018588 | 16.54 |
| 675 | Omega-3 fatty acid levels | GCST90502436 | 16.53 |
| 676 | PLA2G1B/PRSS2 ratio | GCST90315665 | 16.52 |
| 677 | Triglycerides in HDL | GCST90497467 | 16.49 |
| 678 | SNCA levels | GCST90240258 | 16.46 |
| 679 | Triacylglycerol (48:2) [NL-16:0] levels | GCST90025143 | 16.44 |
| 680 | BA-exvivo lh thickness BA4a | GCST90003517 | 16.40 |
| 681 | JAM2/TNFRSF14 ratio | GCST90315240 | 16.39 |
| 682 | Docosahexaenoic acid levels | GCST90502255 | 16.33 |
| 683 | Triacylglycerol_53:5_[M+NH4]1+ levels | GCST90060520 | 16.33 |
| 684 | GALNT10/IGSF3 ratio | GCST90314914 | 16.32 |
| 685 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502593 | 16.31 |
| 686 | Cholesteryl esters to total lipids ratio in medium VLDL | GCST90092919 | 16.31 |
| 687 | LDL cholesterol | GCST90018741 | 16.31 |
| 688 | Haematocrit percentage (UKB data field 30030) | GCST90468073 | 16.29 |
| 689 | APP/VEGFC ratio | GCST90313333 | 16.27 |
| 690 | Freckles | GCST006091 | 16.26 |
| 691 | CNTN3/NCS1 ratio | GCST90314165 | 16.23 |
| 692 | APCS levels | GCST90468328 | 16.22 |
| 693 | PSG1 levels | GCST90470353 | 16.18 |
| 694 | Chronic osteomyelitis (PheCode 710.12) | GCST90476223 | 16.12 |
| 695 | ITGA11 levels | GCST90469633 | 16.10 |
| 696 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502554 | 16.08 |
| 697 | Left-hemisphere salience/ventral attention network to right-hemisphere somatomotor network white-matter structural connectivity | GCST90302713 | 16.08 |
| 698 | CD109 levels | GCST90468597 | 16.07 |
| 699 | Cholesteryl Esters in HDL | GCST90497357 | 16.06 |
| 700 | Cholesteryl esters to total lipids ratio in small HDL | GCST90092947 | 16.06 |
| 701 | Cholesteryl Esters in Medium VLDL | GCST90498928 | 16.04 |
| 702 | CTSF/NAAA ratio | GCST90314314 | 16.02 |
| 703 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T85 | ECGA000085 | 16.02 |
| 704 | FKBP5/MITD1 ratio | GCST90314844 | 15.99 |
| 705 | AXL/IL18BP ratio | GCST90313420 | 15.99 |
| 706 | IDP dMRI ProbtrackX OD str r | GCST90004474 | 15.94 |
| 707 | LILRB2 levels | GCST90469777 | 15.94 |
| 708 | Educational attainment | GCST003496 | 15.88 |
| 709 | Omega-6 fatty acid levels | GCST90502094 | 15.87 |
| 710 | Total lipid levels in HDL | GCST90092825 | 15.87 |
| 711 | Cholesterol levels in very large HDL | GCST90093004 | 15.87 |
| 712 | APOA1 levels | GCST90092808 | 15.87 |
| 713 | Degree of unsaturation | GCST90502225 | 15.83 |
| 714 | Cholesterol in large HDL (UKB data field 23561) | GCST90269658 | 15.80 |
| 715 | HYOU1/TGFBR3 ratio | GCST90315105 | 15.78 |
| 716 | CRNN levels | GCST90468869 | 15.78 |
| 717 | CD93/TNFRSF4 ratio | GCST90313922 | 15.74 |
| 718 | HSD11B1/SMPD1 ratio | GCST90315082 | 15.71 |
| 719 | ICAM1/SELE ratio | GCST90315116 | 15.68 |
| 720 | CTSO/IGF2R ratio | GCST90314317 | 15.67 |
| 721 | PLA2G10 levels | GCST90470244 | 15.65 |
| 722 | Triglycerides in small LDL | GCST90499722 | 15.61 |
| 723 | Irritability | Mental health | UKBB00000380 | 15.61 |
| 724 | Ratio of polyunsaturated fatty acids to monounsaturated fatty acids | GCST90092940 | 15.60 |
| 725 | Cholesterol esters in very large HDL | GCST90500354 | 15.60 |
| 726 | BA-exvivo lh volume BA3a | GCST90002837 | 15.59 |
| 727 | QC dMRI-to-T1 linear alignment discrepancy | GCST90006351 | 15.56 |
| 728 | Concentration of medium HDL particles | GCST90092899 | 15.56 |
| 729 | X-21829 levels | GCST90200585 | 15.55 |
| 730 | IL6ST levels | GCST90469603 | 15.55 |
| 731 | Concentration of large HDL particles (UKB data field 23558) | GCST90269655 | 15.55 |
| 732 | TTR levels | GCST90470985 | 15.54 |
| 733 | SYT1 levels | GCST90470794 | 15.52 |
| 734 | NHLRC3 levels | GCST90470046 | 15.52 |
| 735 | Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454) | GCST90269551 | 15.51 |
| 736 | Omega-3 fatty acid levels | GCST90502425 | 15.50 |
| 737 | Triglycerides to Total Lipids in Large VLDL percentage | GCST90498287 | 15.43 |
| 738 | IDP dMRI ProbtrackX MO str r | GCST90004024 | 15.43 |
| 739 | PON3 levels | GCST90470287 | 15.42 |
| 740 | X-26109 levels | GCST90200671 | 15.42 |
| 741 | SRC/STAT5B ratio | GCST90315882 | 15.42 |
| 742 | CLEC1A/TNFRSF1A ratio | GCST90314085 | 15.42 |
| 743 | 3-Hydroxybutyrate levels | GCST90092811 | 15.39 |
| 744 | ADGRG2 levels | GCST90468241 | 15.36 |
| 745 | CLEC3B levels | GCST90468770 | 15.35 |
| 746 | Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581) | GCST90269678 | 15.35 |
| 747 | Diseases of male genital organs | FING00000426 | 15.34 |
| 748 | Cholesterol levels in very small VLDL | GCST90500712 | 15.34 |
| 749 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501091 | 15.32 |
| 750 | RWDD1/SUMF2 ratio | GCST90315795 | 15.32 |
| 751 | Triglycerides in very small VLDL | GCST90500885 | 15.31 |
| 752 | Total concentration of lipoprotein particles | GCST90500103 | 15.31 |
| 753 | Red blood cell (erythrocyte) distribution width | Blood count | UKBB00000748 | 15.31 |
| 754 | Docosahexaenoic acid levels | GCST90497252 | 15.30 |
| 755 | IDP dMRI TBSS MD External capsule R | GCST90004059 | 15.30 |
| 756 | KITLG levels | GCST90469691 | 15.29 |
| 757 | ACVRL1/EFNA4 ratio | GCST90313156 | 15.22 |
| 758 | ITGB1/TFPI ratio | GCST90315231 | 15.16 |
| 759 | Cholesterol esters in very small VLDL | GCST90500749 | 15.14 |
| 760 | AOC3 levels | GCST90468322 | 15.13 |
| 761 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499199 | 15.12 |
| 762 | DIABLO/VSIR ratio | GCST90314470 | 15.11 |
| 763 | ESAM/TNFRSF14 ratio | GCST90314720 | 15.10 |
| 764 | Docosahexaenoic acid levels | GCST90502243 | 15.09 |
| 765 | Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484) | GCST90269581 | 15.09 |
| 766 | Myopia (PheCode 367.1) | GCST90475880 | 15.09 |
| 767 | Cholesteryl Esters in Small HDL | GCST90499382 | 15.09 |
| 768 | ERBIN/TBC1D23 ratio | GCST90314698 | 15.07 |
| 769 | Total lipid levels in large HDL | GCST90092850 | 15.06 |
| 770 | Triglyceride levels in medium LDL | GCST90092914 | 15.05 |
| 771 | Docosahexaenoic acid to total fatty acids percentage | GCST90502269 | 15.03 |
| 772 | Urine 5-acetylamino-6-amino-3-methyluracil levels in chronic kidney disease | GCST90264674 | 15.01 |
| 773 | Hearing difficulty and hearing difficulty with background noise | GCST90245768 | 14.98 |
| 774 | Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levels | GCST90060423 | 14.98 |
| 775 | Cholesteryl Esters to Total Lipids in Large HDL percentage | GCST90497768 | 14.97 |
| 776 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90132630 | 14.93 |
| 777 | ThalamNuclei lh volume CeM | GCST90002725 | 14.92 |
| 778 | Total cholesterol levels in HDL | GCST90132681 | 14.90 |
| 779 | IDP dMRI ProbtrackX FA str r | GCST90003949 | 14.84 |
| 780 | Triglyceride levels in LDL | GCST90092890 | 14.84 |
| 781 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499194 | 14.84 |
| 782 | Nonalcoholic fatty liver disease | GCST90054782 | 14.81 |
| 783 | Cholesteryl Esters to Total Lipids in Small HDL percentage | GCST90499406 | 14.80 |
| 784 | COMP/ICAM1 ratio | GCST90314189 | 14.76 |
| 785 | Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481) | GCST90269578 | 14.74 |
| 786 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498682 | 14.73 |
| 787 | Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney disease | GCST90264508 | 14.72 |
| 788 | Cholesterol in Large HDL | GCST90497709 | 14.70 |
| 789 | STAMBP levels | GCST90470756 | 14.66 |
| 790 | Glomerular filtration rate (cystatin C) | GCST003375 | 14.65 |
| 791 | Phosphatidylethanolamine (18:0_18:1) levels | GCST90024977 | 14.63 |
| 792 | CRKL/FIS1 ratio | GCST90314266 | 14.63 |
| 793 | Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457) | GCST90269554 | 14.63 |
| 794 | LEPR levels | GCST90469756 | 14.62 |
| 795 | Glycoprotein acetyls levels | GCST90092821 | 14.61 |
| 796 | ESAM/VSIR ratio | GCST90314721 | 14.59 |
| 797 | Cholesteryl ester levels in large HDL | GCST90092846 | 14.58 |
| 798 | Plasma 3-hydroxyhexanoate levels in chronic kidney disease | GCST90264498 | 14.55 |
| 799 | HYOU1/THBD ratio | GCST90315106 | 14.53 |
| 800 | HDL x depression interaction (2df test) | GCST90570667 | 14.52 |
| 801 | aparc-a2009s rh area S-central | GCST90003415 | 14.49 |
| 802 | Free cholesterol in large LDL | GCST90497981 | 14.47 |
| 803 | Hyperglyceridemia (PheCode 272.12) | GCST90475724 | 14.44 |
| 804 | LDL cholesterol | GCST002222 | 14.41 |
| 805 | Diacylglycerol (18:0_18:1) levels | GCST90024714 | 14.40 |
| 806 | Chronic bronchitis (PheCode 496.2) | GCST90476029 | 14.40 |
| 807 | Cholesterol to Total Lipids in IDL percentage | GCST90497511 | 14.39 |
| 808 | GYS1/TIA1 ratio | GCST90315004 | 14.37 |
| 809 | LGALS8/TXNDC5 ratio | GCST90315321 | 14.37 |
| 810 | LYPD8 levels | GCST90469829 | 14.36 |
| 811 | Triglycerides to total lipids in small HDL percentage (UKB data field 23648) | GCST90269745 | 14.36 |
| 812 | DTI TBSS MD Uncinate fasciculus R | GCST90384616 | 14.34 |
| 813 | HDL cholesterol | Blood biochemistry | UKBB00000306 | 14.33 |
| 814 | CD164 levels | GCST90468602 | 14.32 |
| 815 | Total lipids in very small VLDL | GCST90500810 | 14.31 |
| 816 | Cholesteryl Esters in Large HDL | GCST90497751 | 14.30 |
| 817 | DTI TBSS L3 Retrolenticular part of internal capsule L | GCST90384545 | 14.30 |
| 818 | Trihexosylcermide (d18:1/18:0) levels | GCST90024738 | 14.28 |
| 819 | Polyunsaturated fatty acid levels | GCST90502140 | 14.27 |
| 820 | Multi-trait sex score | GCST90270118 | 14.25 |
| 821 | Hypertrophy of breast (Gynecomastia) (PheCode 612.2) | GCST90476163 | 14.23 |
| 822 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500692 | 14.23 |
| 823 | Cholesterol to Total Lipids in Large HDL percentage | GCST90497732 | 14.22 |
| 824 | TOMM20 levels | GCST90470931 | 14.20 |
| 825 | ENTPD6 levels | GCST90469122 | 14.19 |
| 826 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90501002 | 14.17 |
| 827 | Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485) | GCST90269582 | 14.14 |
| 828 | CELA3A/KIRREL2 ratio | GCST90314013 | 14.13 |
| 829 | Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483) | GCST90269580 | 14.13 |
| 830 | HDL cholesterol | GCST002223 | 14.13 |
| 831 | DECR1/METAP1D ratio | GCST90314448 | 14.12 |
| 832 | Free cholesterol levels in large HDL | GCST90092848 | 14.10 |
| 833 | Polyunsaturated fatty acid levels | GCST90499266 | 14.09 |
| 834 | Ascites (non malignant) (PheCode 572) | GCST90476090 | 14.09 |
| 835 | Concentration of large HDL particles | GCST90092851 | 14.09 |
| 836 | Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607) | GCST90269704 | 14.07 |
| 837 | OPTC levels | GCST90470128 | 14.07 |
| 838 | Cholesterol levels in large HDL | GCST90092844 | 14.05 |
| 839 | Triglycerides in small LDL (UKB data field 23550) | GCST90269647 | 14.04 |
| 840 | Acquired absence of organs, not elsewhere classified | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000005 | 14.04 |
| 841 | Phospholipid levels in very large HDL | GCST90132642 | 14.04 |
| 842 | RAB10 levels | GCST90470403 | 14.03 |
| 843 | Estradiol levels | GCST90020091 | 14.02 |
| 844 | Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk | FING00000150 | 14.00 |
| 845 | X-12063 levels | GCST90243687 | 13.98 |
| 846 | Triglycerides in very small VLDL | GCST90500873 | 13.98 |
| 847 | CPE levels | GCST90468841 | 13.98 |
| 848 | GRP levels | GCST90469406 | 13.98 |
| 849 | Hippocampal subfield left CA3 volume (body) | GCST90267940 | 13.97 |
| 850 | IDP dMRI ProbtrackX ICVF cst r | GCST90004384 | 13.96 |
| 851 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90093050 | 13.94 |
| 852 | PON1 levels | GCST90470285 | 13.94 |
| 853 | Triglycerides x anxiety interaction (2df test) | GCST90570677 | 13.93 |
| 854 | Cholesteryl Esters to Total Lipids in Small HDL percentage | GCST90499403 | 13.92 |
| 855 | Phospholipids to total lipids ratio in large HDL | GCST90092853 | 13.90 |
| 856 | REST UKBBICA NET100 1287 | GCST90387141 | 13.90 |
| 857 | Cholesterol to total lipids ratio in small VLDL | GCST90092969 | 13.90 |
| 858 | Phospholipids to Total Lipids in Very Small VLDL percentage | GCST90500856 | 13.90 |
| 859 | High density lipoprotein cholesterol levels | GCST90278635 | 13.90 |
| 860 | CERT/PRTFDC1 ratio | GCST90314029 | 13.87 |
| 861 | Lipoma of skin and subcutaneous tissue (PheCode 214.1) | GCST90475619 | 13.86 |
| 862 | DBI levels | GCST90468949 | 13.86 |
| 863 | Free cholesterol in small VLDL | GCST90499817 | 13.85 |
| 864 | Chronic Kidney Disease, Stage IV (PheCode 585.34) | GCST90476130 | 13.85 |
| 865 | QC tfMRI-to-T1 linear alignment discrepancy | GCST90006354 | 13.84 |
| 866 | CES3 levels | GCST90468720 | 13.84 |
| 867 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502147 | 13.80 |
| 868 | CD69/SNAP29 ratio | GCST90313887 | 13.78 |
| 869 | Phosphoglycerides levels | GCST90499265 | 13.78 |
| 870 | ALB levels | GCST90018725 | 13.77 |
| 871 | LSP1/NADK ratio | GCST90315331 | 13.77 |
| 872 | Hearing difficulty with background noise | GCST90245775 | 13.77 |
| 873 | Cholesteryl ester levels in very large HDL | GCST90093006 | 13.76 |
| 874 | Free cholesterol to total lipids ratio in small LDL | GCST90092961 | 13.75 |
| 875 | aseg global volume BrainSeg | GCST90002590 | 13.74 |
| 876 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500373 | 13.74 |
| 877 | Triglycerides in small VLDL | GCST90499915 | 13.74 |
| 878 | CNTN5/ROBO2 ratio | GCST90314166 | 13.74 |
| 879 | ERP44/SUMF2 ratio | GCST90314710 | 13.73 |
| 880 | Free cholesterol in large HDL (UKB data field 23563) | GCST90269660 | 13.73 |
| 881 | DTI TBSS MD Retrolenticular part of internal capsule L | GCST90384593 | 13.72 |
| 882 | Basophil count variance | GCST90565682 | 13.71 |
| 883 | Cholesterol levels in very small VLDL | GCST90500700 | 13.71 |
| 884 | Brain glioblastoma, excluding all cancers (controls excluding all cancers) | FING00000225 | 13.70 |
| 885 | Nephritis and nephropathy without mention of glomerulonephritis (PheCode 580.3) | GCST90476115 | 13.68 |
| 886 | PRKAR1A levels | GCST90470326 | 13.65 |
| 887 | X-04499--3,4-dihydroxybutyrate levels | GCST90243497 | 13.64 |
| 888 | 1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels | GCST90200067 | 13.64 |
| 889 | EPO/TFRC ratio | GCST90314684 | 13.63 |
| 890 | Concentration of HDL particles (UKB data field 23430) | GCST90269527 | 13.63 |
| 891 | Total cholines levels | GCST90497183 | 13.62 |
| 892 | AXIN1/GOPC ratio | GCST90313407 | 13.62 |
| 893 | Cholesteryl ester_14:0_[M+NH4]1+ levels | GCST90060197 | 13.62 |
| 894 | Familial combined hyperlipidemia defined by Dutch criteria | GCST90104005 | 13.59 |
| 895 | Sleep apnea (MTAG) | GCST90267362 | 13.58 |
| 896 | EPHB4/ESAM ratio | GCST90314679 | 13.57 |
| 897 | Triglyceride to HDL cholesterol ratio | GCST90295949 | 13.56 |
| 898 | Cyst of kidney, acquired (PheCode 586.2) | GCST90476133 | 13.55 |
| 899 | IDP dMRI TBSS OD Posterior limb of internal capsule R | GCST90004420 | 13.54 |
| 900 | STAMBP/WWP2 ratio | GCST90315888 | 13.51 |
| 901 | Cholelithiasis | Disorders of gallbladder, biliary tract and pancreas | UKBB00000132 | 13.49 |
| 902 | Cholesteryl esters to total lipids ratio in very small VLDL | GCST90093031 | 13.47 |
| 903 | FAM171B levels | GCST90469183 | 13.46 |
| 904 | RNASEH2A levels | GCST90470480 | 13.46 |
| 905 | Hypertrophy of breast | FING00000644 | 13.44 |
| 906 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500397 | 13.44 |
| 907 | CST6 levels | GCST90468896 | 13.42 |
| 908 | IDP dMRI ProbtrackX MO str l | GCST90004023 | 13.41 |
| 909 | ERN1 levels | GCST90469148 | 13.40 |
| 910 | aparc-a2009s rh area G+S-occipital-inf | GCST90003372 | 13.40 |
| 911 | CD63/CLEC1B ratio | GCST90313863 | 13.40 |
| 912 | Marzipan liking | GCST90094797 | 13.38 |
| 913 | PLIN3/TYMP ratio | GCST90315678 | 13.34 |
| 914 | Phospholipids in small VLDL | GCST90499871 | 13.33 |
| 915 | Free cholesterol to total lipids ratio in small HDL | GCST90092949 | 13.32 |
| 916 | Hyperlipidemia | GCST90090994 | 13.32 |
| 917 | Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486) | GCST90269583 | 13.30 |
| 918 | Cholesterol in medium HDL (UKB data field 23568) | GCST90269665 | 13.27 |
| 919 | APOA1 levels | GCST90468331 | 13.26 |
| 920 | Vegetarianism | GCST90428838 | 13.25 |
| 921 | IDP dMRI TBSS L2 Middle cerebellar peduncle | GCST90004123 | 13.24 |
| 922 | T1 FreeSurfer aseg Left-choroid-plexus | GCST90384156 | 13.24 |
| 923 | Dihexosylceramide (d18:1/22:0) levels | GCST90025348 | 13.24 |
| 924 | Degree of unsaturation | GCST90500175 | 13.24 |
| 925 | Triglycerides in small HDL (UKB data field 23578) | GCST90269675 | 13.24 |
| 926 | Otosclerosis | GCST90129575 | 13.23 |
| 927 | Triglycerides in small VLDL (UKB data field 23515) | GCST90269612 | 13.21 |
| 928 | ENG/NOTCH1 ratio | GCST90314648 | 13.18 |
| 929 | Free cholesterol in medium LDL | GCST90498767 | 13.17 |
| 930 | Phospholipids to total lipids ratio in small LDL | GCST90092965 | 13.13 |
| 931 | Phosphatidylcholine-O_44:5_[M+OAc]1-/Phosphatidylcholine-P_44:4_[M+OAc]1- levels | GCST90060557 | 13.13 |
| 932 | aparc-DKTatlas lh volume caudalanteriorcingulate | GCST90002863 | 13.12 |
| 933 | DAB2/ZBTB16 ratio | GCST90314370 | 13.12 |
| 934 | PCDH17/SEMA7A ratio | GCST90315605 | 13.10 |
| 935 | S100A11 levels | GCST90470512 | 13.08 |
| 936 | Cholesterol to Total Lipids in Small HDL percentage | GCST90499369 | 13.07 |
| 937 | PPP1R2/TMSB10 ratio | GCST90315721 | 13.04 |
| 938 | Stable angina pectoris | GCST90018695 | 13.02 |
| 939 | Red cell distribution width | GCST90025988 | 13.02 |
| 940 | Phospholipids in medium HDL | GCST90498635 | 13.01 |
| 941 | CRHBP/TREM2 ratio | GCST90314260 | 13.00 |
| 942 | Cigarettes smoked per day (MTAG) | GCST90179151 | 13.00 |
| 943 | CSF1/LTBR ratio | GCST90314287 | 13.00 |
| 944 | Free cholesterol to total lipids ratio in medium HDL | GCST90092897 | 12.99 |
| 945 | Free cholesterol to total lipids ratio in small VLDL | GCST90092973 | 12.99 |
| 946 | APOB/APOA1 ratio | GCST90269538 | 12.99 |
| 947 | IDP dMRI ProbtrackX MD ar l | GCST90004219 | 12.99 |
| 948 | DNAJB1/PPME1 ratio | GCST90314510 | 12.96 |
| 949 | Triglycerides in very large VLDL (UKB data field 23494) | GCST90269591 | 12.95 |
| 950 | CLIP2/DNAJA2 ratio | GCST90314127 | 12.92 |
| 951 | Total lipids in very large HDL (UKB data field 23552) | GCST90269649 | 12.91 |
| 952 | aseg global volume SupraTentorial | GCST90002595 | 12.90 |
| 953 | FGR levels | GCST90469236 | 12.89 |
| 954 | Omega-3 fatty acids to total fatty acids percentage | GCST90499163 | 12.87 |
| 955 | SBSN levels | GCST90470531 | 12.84 |
| 956 | ADGRG2/NRCAM ratio | GCST90313186 | 12.83 |
| 957 | Average diameter for VLDL particles | GCST90500290 | 12.83 |
| 958 | Omega-6 fatty acids levels | GCST90499170 | 12.80 |
| 959 | STC2 levels | GCST90470762 | 12.78 |
| 960 | Polyunsaturated fatty acid levels | GCST90499271 | 12.78 |
| 961 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T96 | ECGU000096 | 12.76 |
| 962 | Worrier / anxious feelings | Mental health | UKBB00000921 | 12.75 |
| 963 | X-23641 levels | GCST90200603 | 12.75 |
| 964 | DECR1/MAP2K6 ratio | GCST90314447 | 12.74 |
| 965 | aparc-Desikan lh thickness postcentral | GCST90003466 | 12.74 |
| 966 | ENDOU levels | GCST90469107 | 12.73 |
| 967 | ICAM2/SELE ratio | GCST90315120 | 12.73 |
| 968 | ENG levels | GCST90469108 | 12.72 |
| 969 | Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH] (PheCode 573.6) | GCST90476094 | 12.69 |
| 970 | Retinal detachments and defects (PheCode 361) | GCST90475845 | 12.69 |
| 971 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T135 | ECGA000135 | 12.67 |
| 972 | Cholesteryl Esters in IDL | GCST90497525 | 12.67 |
| 973 | Hands-free device/speakerphone use with mobile phone in last 3 month | Electronic device use | UKBB00000304 | 12.64 |
| 974 | Red blood cell erythrocyte distribution width (UKB data field 30070) | GCST90468099 | 12.64 |
| 975 | PVR levels | GCST90470394 | 12.63 |
| 976 | Free cholesterol to total lipids ratio in medium LDL | GCST90092909 | 12.63 |
| 977 | ANGPT1/SERPINE1 ratio | GCST90313269 | 12.63 |
| 978 | APOE levels | GCST90468338 | 12.60 |
| 979 | Free cholesterol levels in HDL | GCST90092824 | 12.60 |
| 980 | Smoking dependency | FING00001315 | 12.60 |
| 981 | Cheese intake | Diet | UKBB00000127 | 12.58 |
| 982 | Triglycerides in large HDL | GCST90497888 | 12.57 |
| 983 | aparc-Desikan lh volume precentral | GCST90002791 | 12.57 |
| 984 | Phospholipid levels in small HDL | GCST90092952 | 12.56 |
| 985 | IDP dMRI ProbtrackX MD cst l | GCST90004227 | 12.55 |
| 986 | Triglycerides to Total Lipids in Very Small VLDL percentage | GCST90500900 | 12.55 |
| 987 | Phospholipids in medium HDL | GCST90498641 | 12.55 |
| 988 | Triglycerides in medium HDL | GCST90498667 | 12.54 |
| 989 | IDP dMRI TBSS L2 Corticospinal tract R | GCST90004129 | 12.51 |
| 990 | Saturated fatty acids levels | GCST90502186 | 12.50 |
| 991 | Androstenediol (3alpha, 17alpha) monosulfate (3) levels | GCST90199856 | 12.49 |
| 992 | Triglycerides in HDL (UKB data field 23410) | GCST90269507 | 12.49 |
| 993 | Phospholipids in medium LDL | GCST90498832 | 12.48 |
| 994 | Phospholipids to total lipids in large HDL percentage (UKB data field 23634) | GCST90269731 | 12.47 |
| 995 | BCAN/CD200 ratio | GCST90313477 | 12.47 |
| 996 | Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641) | GCST90269738 | 12.46 |
| 997 | Cholesteryl Esters in Large LDL | GCST90497955 | 12.44 |
| 998 | aparc-DKTatlas lh thickness postcentral | GCST90003560 | 12.43 |
| 999 | APOB/APOA1 ratio | GCST90497156 | 12.40 |
| 1000 | LTBP2 levels | GCST90469814 | 12.39 |